In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Disrupters

Executive Summary

The endless cycle of mergers is no answer to the basic growth problems of now oversized pharmaceutical companies, in part because little real restructuring goes on with the acquirer, who needs it as much as the target. But one set of acquirers we haven't heard from could accomplish a lot of the necessary reforms: the large IT companies who could apply not only their technologies to improve marketing and business practices in the drug industry, but their management philosophies.
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel